What You Should Know:
– C the Signs, a developer of AI-powered cancer detection solutions, today announced an $8 million funding round led by Khosla Ventures.
– The investment will fuel the company’s expansion from the United Kingdom, where it has already achieved significant success in early cancer detection, to the United States.
Cancer Screening and Improve Patient Outcomes
C the Signs addresses a critical gap in cancer care by identifying patients at risk of cancer at the earliest and most treatable stages. The company’s AI platform analyzes patient electronic health records (EHRs) to assess individual cancer risk, going beyond basic risk factors like age and gender to examine a wide range of personal and environmental data points. By detecting tumors at earlier stages, when they are more likely to be curable, C the Signs aims to significantly improve cancer survival rates. The company’s AI platform is a valuable tool for healthcare providers, enabling them to deliver more proactive and personalized care to their patients.
This personalized approach allows C the Signs to:
- Flag high-risk individuals: Identify patients who require targeted testing and early intervention.
- Reduce unnecessary screenings: Rule out patients who are not at high risk, reducing the burden on primary care physicians and healthcare resources.
- Improve early detection rates: Detect cancers earlier, when they are most treatable, leading to better patient outcomes.
Proven Success in the UK
C the Signs has demonstrated impressive results within the UK’s National Health Service (NHS), where its AI platform has:
- Identified 20.7% of breast cancer cases up to five years earlier than standard pathways.
- Improved early-stage diagnosis of ovarian cancer by 53.3% compared to traditional methods.
“We started C the Signs to move the burden of identifying cancer risk away from the emergency room, when it’s often too late. Instead, we want to enable primary care physicians to identify cancer risk at the earliest possible stage, to substantially increase the chance of survival,” said C the Signs Co-Founder and CEO Dr. Bea Bakshi, MD. “Cancer has a timeline — from curable to incurable — and time to diagnosis can mean the difference between life and loss. We’re grateful that Khosla Ventures recognises the urgency of getting this technology into the hands of as many doctors as possible. Together, we’re working toward a future where every patient has the best possible chance of surviving cancer.”
